Surfaxin

lucinactant

FDA Accepts Discovery Labs' Complete Response to Approvable Letter for Surfaxin

WARRINGTON, Pa., October 21, 2005 -- Discovery Laboratories, Inc. (Nasdaq:DSCO) has been informed today by the U.S. Food and Drug Administration (FDA) that the FDA has accepted Discovery's resubmission of October 5, 2005 as a complete response to the Approvable Letter for Surfaxin, for the prevention of Respiratory Distress Syndrome (RDS) in premature infants. The FDA has established April 2006 as its target to complete its review of the Surfaxin New Drug Application (NDA).

Robert J. Capetola, Ph.D., President and Chief Executive Officer of Discovery, commented, "With the acceptance of our response to the Surfaxin Approvable Letter, the FDA six-month review process has begun as of October 5, 2005, the date of our resubmission. Discovery will work diligently with the FDA during this review, which will include the reinspection of our Surfaxin contract manufacturing facility, Laureate Pharma in Totowa, New Jersey. We anticipate that Surfaxin, the first precision-engineered Surfactant Replacement Therapy, will be available to the neonatal medical community in the second quarter of 2006."

Surfaxin is a precision-engineered, peptide-containing, synthetic surfactant that is designed to closely mimic the function of natural human lung surfactant and represents a potential alternative for the animal-derived and non-protein containing synthetic surfactants. Discovery's Surfaxin has received an Approvable Letter from the FDA for the prevention of RDS in premature infants and is pending approval. Surfactants are substances that are produced naturally in the lungs and are essential to the lungs' ability to absorb oxygen and to maintain proper airflow through the respiratory system. Premature babies are born with a lack of natural surfactant in their lungs. Without surfactant, the air sacs in the lungs collapse and are unable to absorb sufficient oxygen resulting in RDS.

Source: Discovery Laboratories, Inc.

Related Articles:

Discovery Labs Provides Guidance On FDA Approvable Letter for Surfaxin for RDS - May 5, 2008

Discovery Labs Receives An Approvable Letter From FDA for Surfaxin for RDS - May 2, 2008

Discovery Labs' Response to Surfaxin Approvable Letter Deemed Complete by FDA - November 16, 2007

Discovery Labs Submits Response to FDA Approvable Letter for Surfaxin for RDS in Premature Infants - November 1, 2007

Surfaxin Process Validation Batches Achieve Stability Milestone to Enable Filing of Response to FDA Approvable Letter - October 1, 2007

Discovery Labs Provides Update On Progress for Surfaxin for RDS - August 2, 2007

Discovery Labs and FDA Reach Clarity On Path Towards Surfaxin RDS Approval - January 22, 2007

Discovery Labs Updates Progress On Manufacturing Remediation and Surfaxin FDA Regulatory Matters - September 28, 2006

Discovery Labs Receives Second Approvable Letter From FDA for Surfaxin for RDS - April 5, 2006

Discovery Labs Provides Update on Status of Response to FDA Approvable Letter for Surfaxin - August 19, 2005

Discovery Labs Provides Status of Previously Submitted Response to FDA Approvable Letter for Surfaxin - August 15, 2005

Discovery Labs Submits Response to FDA Approvable Letter for Surfaxin for RDS in Premature Infants - July 29, 2005

Discovery Labs Receives Approvable Letter from FDA for Surfaxin for Respiratory Distress Syndrome in Premature Infants - February 14, 2005

Discovery Laboratories Announces FDA Acceptance of Surfaxin New Drug Application - June 15, 2004

Discovery Laboratories Files New Drug Application with the FDA to Market Surfaxin for the Prevention of Respiratory Distress Syndrome in Premature Infants - April 14, 2004

Latest New Drug Applications...

Pharma News
New Drug Applications
New Drug Approvals
Clinical Trial Results
Generic Drug Approvals